Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 2/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3038765 | 0.87 | ALDH1A1 (0.52) | FFAR4TRPV4PGRAHRALDH1A1 | |
| SCHEMBL11881437 | 0.87 | ALDH1A1 (0.46) | FFAR4TRPV4ALDH1A1PKMCYP1A2 | |
| SCHEMBL18700980 | 0.82 | PGR (0.43) | FFAR4PGRAHRALDH1A1PKM | |
| SCHEMBL28188557 | 0.80 | RAPGEF4 (0.43) | FFAR4TRPV4ALDH1A1PKMLMNA | |
| SCHEMBL20258658 | 0.79 | ALOX15 (0.41) | TRPV4ALDH1A1LMNATP53 | |
| SCHEMBL18331985 | 0.78 | FFAR4 (0.41) | FFAR4TRPV4ALDH1A1PKMNAMPT | |
| SCHEMBL31314383 | 0.78 | MAPT (0.38) | FFAR4TRPV4ALDH1A1PKMLMNA | |
| SCHEMBL19024616 | 0.78 | CYP3A4 (0.38) | FFAR4TRPV4PGRALDH1A1PKM | |
| SCHEMBL13584602 | 0.78 | MAPT (0.38) | FFAR4TRPV4ALDH1A1PKMLMNA | |
| SCHEMBL184464 | 0.78 | TSHR (0.47) | PGRALDH1A1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10793522-B2 | Sulfonamides as inhibitors of the uptake of extracellular citrate | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-10-06 | — | — | US | disclosed |
| EP-3551618-B1 | SULFONAMIDES AS INHIBITORS OF THE UPTAKE OF EXTRACELLULAR CITRATE | BOEHRINGER INGELHEIM INT (DE) | 2020-09-16 | — | — | EP | disclosed |
| US-20200062708-A1 | SULFONAMIDES AS INHIBITORS OF THE UPTAKE OF EXTRACELLULAR CITRATE | BOEHRINGER INGELHEIM PHARMA GBMH & CO KG (DE) | 2020-02-27 | — | — | US | disclosed |
| WO-2018104220-A1 | SULFONAMIDES AS INHIBITORS OF THE UPTAKE OF EXTRACELLULAR CITRATE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-06-14 | — | — | WO | disclosed |
| US-8232312-B2 | Substituted arylsulphonylglycines, the preparation thereof and the use thereof as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-8232312-B2 | Substituted arylsulphonylglycines, the preparation thereof and the use thereof as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-8232312-B2 | Substituted arylsulphonylglycines, the preparation thereof and the use thereof as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| EP-2125718-B1 | NEW SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2010-09-15 | — | — | EP | disclosed |
| US-20100130557-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-27 | — | — | US | disclosed |
| US-20100130557-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-27 | — | — | US | disclosed |
| US-20100130557-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-27 | — | — | US | disclosed |
| WO-2008113760-A2 | ARYLSULPHONYGLYCINE DERIVATIVES AS SUPPRESSORS OF THE INTERACTION OF GLYCOGEN PHOSPHORYLASE A WITH THE GL SUBUNIT OF GLYCOGEN-ASSOCIATED PROTEIN PHOSPHATASE 1 (PPL) FOR THE TREATMENT OF METABOLIC DISORDERS, PARTICULARY DIABETES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062708-A1 | SULFONAMIDES AS INHIBITORS OF THE UPTAKE OF EXTRACELLULAR CITRATE | CS, GLS, GLS2 | FFAR4 1030/4885TRPV4 1694/4885PGR 2817/4885 |
| US-10793522-B2 | Sulfonamides as inhibitors of the uptake of extracellular citrate | CS, GLS, GLS2 | FFAR4 1030/4885TRPV4 1694/4885PGR 2817/4885 |
| US-20100130557-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | PYGL, PYGM, G6PC1 | FFAR4 3586/4885TRPV4 4851/4885PGR 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.